Two years after the close of the merger that formed Viatris, the company is acquiring Oyster Point Pharma and Famy Life Sciences to expand its scope in ophthalmology, one of three therapeutic areas it is now focusing on for revenue growth.
Financial terms of the deal were kept confidential. Novartis will work with Ubisoft and McGill University to accelerate development of a digital therapeutic for amblyopia, also known as lazy eye.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
While well-developed in cancers, precision medicine's readiness for prime time beyond oncology varies markedly from disease to disease. But reimbursement remains a significant hurdle.
Shares of Philadelphia-based Spark were up more than 120 percent in premarket trading on the Nasdaq following the news.
Miki Kapoor replaces Doug Foster, who will continue as chief strategy officer of the San Francisco-based company.
One goal of FocalView is to create a more accurate way to track and measure disease progression and develop more sensitive clinical trial endpoints from the comfort of patients' homes., adding more flexibility to clinical trial design.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Opternative's complaint against eyewear retailer Warby Parker alleges that Warby violated non disclosure agreements and trade secrets to develop a rival eye exam app.
Spark Therapeutics' treatment would mark a milestone for gene therapy to treat eye diseases and could help children and adults avoid irreversible blindness.
The dry eye disease treatment space has been fairly active in the past few years from a combination of new companies and M&A deals in this area.
On the last day of the ATA conference, three panelists explored the value in telemedicine and why it's key to apply the KISS (keep it simple, stupid) principle.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
If Google is able to overcome the many hurdles to bringing this device to market, it could revolutionize the eye care industry. “What’s in their patent is the Holy Grail for patients over 40 years old," said Dr. Jeffrey Sonsino, an optometrist in Nashville, Tennessee.
The yet-unnamed app, for iPhone and iPad, is intended to provide decision support — via the IBM Cloud — and assist in the selection of implantable intraocular lenses.
Opternative offers its online eye exam to "healthy" 18-40 year olds in 32 states so fat and is keen to ramp that up.
"Cyborg brains," in the form of brain implants, are in development at the University of Southern California.
An MIT mobile health spinoff wants to bring vision tests to smartphones and has raised $4 million as part of a Series A round. In a phone interview with MedCity News, EyeNetra COO and co-founder David Schafran confirmed the fundraise but was fairly tight-lipped about details such as how the tests would be delivered and […]